121 Results for "

item/HY-B0015

" in MedChemExpress (MCE) Product Catalog:
Products (121)

121 Results for "item/HY-B0015" in MCE Product Catalog:

  • Targets Recommended:
396
396 Publications Verification
Cat. No.: HY-B0015
CAS No.: 33069-62-4
Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy .
loading...
    loading...
136
136 Cited Publications
Cat. No.: HY-15244
CAS No.: 1217486-61-7
Purity:  99.88%
Synonyms: BYL-719
Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
loading...
    loading...
136
136 Cited Publications
Cat. No.: HY-15244A
CAS No.: 1584128-91-5
Synonyms: BYL-719 HYdrochloride
Alpelisib (BYL-719) hydrochloride is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib hydrochloride also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib hydrochloride not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib hydrochloride can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-N0256
CAS No.: 465-99-6
Hederagenin is a triterpenoid saponin with orally active and antitumor activity. Hederagenin can inhibit the expression of iNOS, COX-2, and NF-κB in cells induced by LPS stimulation. Hederagenin also increases ROS production in cancer cells, disrupts mitochondrial membrane potential, and induces apoptosis. Hederagenin also sensitizes cancer cells to Cisplatin (HY-17394) and Paclitaxel (HY-B0015), enhancing induced apoptosis. Hederagenin can also bind to SKP2, with KD = 67.9 μM. Hederagenin also has preventive potential against alcoholic liver injury .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-P99974
Synonyms: Nanoparticle albumin-bound Paclitaxel; Nanoparticle albumin-bound ABI-007

Research Areas:  

Cancer

Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and solid tumors. (The product specifications below only indicate the effective content of Paditaxel, the actual albumin quality depends on the batch; the ratio of each ingredient in this product is Paditaxel: albumin -1:7~1:11) .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-15898
CAS No.: 288250-47-5
Purity:  99.03%
Y-320 is a potent, orally active phenylpyrazoleanilide immunomodulator. Y-320 inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 values of 20 to 60 nM. Y-320 enhances TP53, DMD, and COL17A1 PTC readthrough by G418 and increases cellular protein levels and protein synthesis. Y-320 concomitants use of with a low dose of Paclitaxel (HY-B0015) significantly sensitized multidrug resistance (MDR) tumors by inducing G2/M phase arrest and apoptosis. Y-320 can be used for research of rheumatoid arthritis (RA) and cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-150231
CAS No.: 2376580-08-2
Purity:  99.77%
Target:  

YB-1

Research Areas:  

Cancer

SU056 is a YB-1 inhibitor. SU056 induces cell-cycle arrest, apoptosis, and inhibits cell migration in ovarian cancer cells. SU056 interacts with YB-1 and inhibits and its associated downstream proteins and pathways. SU056 can enhance the cytotoxic effects of Paclitaxel (HY-B0015) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-19536
CAS No.: 1260247-42-4
Target:  

STAT

Research Areas:  

Cancer

LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99279
CAS No.: 648904-28-3
Synonyms: Anti-Human Phosphatidylserine Recombinant Antibody; PGN-401; CH3G4

Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-144878
CAS No.: 2361742-30-3
Purity:  99.93%
Target:  

c-Myc

Research Areas:  

Cancer

VPC-70619 is a potent N-Myc inhibitor. VPC-70619 blocks the binding of the N-Myc-Max heterocomplex to the DNA E-box and exhibits potent inhibitory activity against N-Myc-dependent cell lines. VPC-70619 can partially reverse paclitaxel (HY-B0015) resistance in cells by reducing MYCN expression. VPC-70619 can be used for cancer research (e.g., neuroblastoma and thyroid cancer) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-103019
CAS No.: 1610408-97-3
Purity:  99.89%
Synonyms: (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib
Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor (IC50=3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II. Enitociclib specifically depletes key short-lived proteins such as c-MYC, MCL-1 and induces tumor cell apoptosis. Enitociclib also interferes with the production of enhancer RNAs (eRNA) and enhancer-promoter interactions, and downregulates oncogene expression at the epigenetic level. Enitociclib exerts synergistic effects with agents including Bortezomib (HY-10227), Lenalidomide (HY-A0003), Pomalidomide (HY-10984), Venetoclax (HY-15531) and Paclitaxel (HY-B0015), and even reverses paclitaxel resistance. Enitociclib serves as a vital research tool for various malignancies such as double-hit diffuse large B-cell lymphoma, multiple myeloma and pancreatic ductal adenocarcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0415
CAS No.: 67-73-2
Fluocinolone is a glucocorticoid glucocorticoid receptor agonist. Fluocinolone is effective in preventing both lipid accumulation and inflammation. Fluocinolone can promote the proliferation of DPCs and has the potential role in repairing injured pulp tissues. Fluocinolone can be used to study the prevention of chemotherapy-induced peripheral neuropathy caused by Paclitaxel (HY-B0015) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0015R
CAS No.: 33069-62-4
Paclitaxel (Standard) is the analytical standard of Paclitaxel. This product is intended for research and analytical applications. Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-16160
CAS No.: 851636-83-4
Target:  

Autophagy ICMT

Research Areas:  

Neurological Disease Cancer

Cysmethynil is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N4208
CAS No.: 2230777-09-8
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

Taccalonolide AJ is a microtubule stabilizer and antiproliferative agent with an IC50 of 4.2 nM against β-tubulin (β-tubulin) D226. Taccalonolide AJ increases cellular microtubule density, induces microtubule bundling, triggers G2/M cell cycle arrest with abnormal mitotic spindles, and inhibits cancer cell proliferation. Taccalonolide AJ can be used in the research of oral cancer, breast cancer, solid tumors, as well as tumors resistant to Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A) .
loading...
    loading...
Cat. No.: HY-401424
CAS No.: 61791-12-6
Synonyms: PolyoxyetHYlene(36) Castor Oil; PEG-36 Castor Oil
Cremophor EL-36 is a non-ionic surfactant, mainly used as a solubilizing carrier for poorly soluble Paclitaxel (HY-B0015). For example, Cremophor EL-36 can enhance the intracellular influx of Etoposide (HY-13629) without affecting drug efflux, and can dose-dependently increase the accumulation of VP-16 in lung adenocarcinoma cells (such as PC-14 and A549), significantly enhancing its cytotoxic effect .
loading...
    loading...
Cat. No.: HY-P4073
CAS No.: 1075214-55-9
Synonyms: GRN1005; Paclitaxel trevatide
Research Areas:  

Cancer

ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .
loading...
    loading...
Cat. No.: HY-125348
CAS No.: 153212-75-0
Purity:  99.93%
Target:  

Drug Metabolite

Research Areas:  

Cancer

6α-Hydroxy paclitaxel is one of the main metabolites of Paclitaxel (PTX) (HY-B0015), and it is generated by the liver cytochrome P450 enzyme CYP2C8. 6α-Hydroxy paclitaxel has bone marrow toxicity, but it can enhance the cytotoxicity of PTX against leukemia cells without causing cell toxicity. 6α-Hydroxy paclitaxel can be used in leukemia research .
loading...
    loading...
Cat. No.: HY-B0015S
CAS No.: 1129540-33-5
Paclitaxel-d5 is a deuterium-labeled Paclitaxel. Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization .
loading...
    loading...
Cat. No.: HY-149449
CAS No.: 208106-41-6
Poly-L-γ-glutamic acid sodium is a macromolecular polymer formed by the linkage of glutamic acid residues via peptide bonds between γ-amino and carboxyl groups. Poly-L-γ-glutamic acid sodium plays an important role as a carrier material in compound delivery systems. Poly-L-γ-glutamic acid sodium can deliver Paclitaxel (HY-B0015) to colon cancer cells, reduce cell viability and inhibit the growth of colon cancer spheroids. Poly-L-γ-glutamic acid sodium can be used as a carrier material and in studies related to colon cancer in mice .
loading...
    loading...